ArticleAntimicrobial agents and chemotherapy2017
Screening the Pathogen Box for Identification of Candida albicans Biofilm Inhibitors.
Article in Antimicrobial agents and chemotherapy, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 67 citations in OpenAlex.
- Article
- Auranofin and iodoquinol as promising repurposing drugs against filamentous fungi: antifungal activity and cellular alterations.Microbiology spectrum · 2026Article
- Secondary Metabolites of the Marine Sponge-Derived FungusMarine drugs · 2025Article
- Chemical Composition, Biocompatibility, and Anti-Pathogens (Basel, Switzerland) · 2025Article
- Pentamidine inhibition of streptopain attenuatesMicrobiology spectrum · 2025Article
- Pentamidine inhibition of streptopain attenuatesbioRxiv : the preprint server for biology · 2025Article
- The lichen secondary metabolite lichesterinic acid exhibits antibiofilm activity against fungal pathogens.Frontiers in cellular and infection microbiology · 2025Article
- In vitro antifungal activity of MMV Pathogen Box® compounds alone or in combination with antifungal drugs against mucormycosis agents.Current research in microbial sciences · 2024Article
- Medicines for Malaria Venture Pandemic Box In Vitro Screening Identifies Compounds Highly Active against the Tachyzoite Stage ofTropical medicine and infectious disease · 2023Article
- Screening the medicine for malaria venture's Pandemic Response Box to identify novel inhibitors of Candida albicans and Candida auris biofilm formation.APMIS : acta pathologica, microbiologica, et immunologica Scandinavica · 2023Article
- Screening of MMV pandemic response and pathogen box compounds against pan-drug-resistantNew microbes and new infections · 2023Article
- Candida albicans antibiofilm molecules: analysis based on inhibition and eradication studies.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2023Review
- Sources of Antifungal Drugs.Journal of fungi (Basel, Switzerland) · 2023Review
- Pandemic Response Box® library as a source of antifungal drugs against Scedosporium and Lomentospora species.PloS one · 2023Article
- Article
- The Anticancer Drug Bleomycin Shows Potent Antifungal Activity by Altering Phospholipid Biosynthesis.Microbiology spectrum · 2022Article
- Preliminary Structure-Activity Relationship Study of the MMV Pathogen Box Compound MMV675968 (2,4-Diaminoquinazoline) Unveils Novel Inhibitors ofMolecules (Basel, Switzerland) · 2022Article
- Temporal and Wash-Out Studies Identify Medicines for Malaria Venture Pathogen Box Compounds with Fast-Acting Activity against BothMicroorganisms · 2022Article
- Evaluation of the Anti-Pharmaceutics · 2022Article
- The Pandemic Response Box─Accelerating Drug Discovery Efforts after Disease Outbreaks.ACS infectious diseases · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
Candida albicans remains the main causative agent of candidiasis, one of the most frequent nosocomial infections, with unacceptably high mortality rates. Biofilm formation is a major risk factor for invasive candidiasis, as Candida biofilms display high-level resistance to most antifungal agents. In this work we have screened the Pathogen Box chemical library (Medicines for Malaria Venture [MMV], Switzerland) in search for inhibitors of C. albicans biofilm formation. Our initial screen identified seven hits, and additional dose-response assays confirmed the biofilm-inhibitory activity of six of these small molecules. Three compounds, MMV688768, MMV687273, and MMV687807, were also able to reduce the metabolic activity of cells within preformed biofilms. Interestingly, the most potent of these, compound MMV688768, displayed increased antibiofilm activity compared to its activity against planktonic cultures, indicating that it may affect processes with a predominant role during the biofilm mode of growth. This compound demonstrated a high selectivity index when its antibiofilm activity was compared with its toxicity in liver hepatocellular cells. In vitro combination assays showed a synergistic interaction between compound MMV688768 and fluconazole against preformed biofilms. Overall, our results indicate that this compound may constitute a potential candidate for further clinical development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.